Sahu T, Pande B, PL M, Verma HK. Liver dysfunction during COVID-19 pandemic: Contributing role of associated factors in disease progression and severity. World J Hepatol 2022; 14(6): 1099-1110 [PMID: 35978661 DOI: 10.4254/wjh.v14.i6.1099]
Corresponding Author of This Article
Henu Kumar Verma, PhD, Research Scientist, Senior Researcher, Department of Immunopathology, Institute of Lungs Health and Immunity, Ingolstädter Landstrasse 1, Munich 85764, Bavaria, Germany. henu.verma@yahoo.com
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Tarun Sahu, Babita Pande, Department of Physiology, All India Institute of Medical Sciences, Raipur 492001, Chhattisgarh, India
Manasa PL, Center for Basic Sciences, Pt. Ravishankar Shukla University, Raipur 492001, Chhattisgarh, India
Henu Kumar Verma, Department of Immunopathology, Institute of Lungs Health and Immunity, Munich 85764, Bavaria, Germany
Author contributions: Verma HK designed the review; Sahu T, Manasa PL, and Pande B performed the literature search and collected and assembled the data; HKV and BP analyzed the obtained articles; Sahu T, Manasa PL, Pande B, and Verma HK wrote the manuscript and revised it critically; all authors have read and agreed to the published version of the manuscript.
Conflict-of-interest statement: The authors declare that there is no potential conflict of interest to disclose.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Henu Kumar Verma, PhD, Research Scientist, Senior Researcher, Department of Immunopathology, Institute of Lungs Health and Immunity, Ingolstädter Landstrasse 1, Munich 85764, Bavaria, Germany. henu.verma@yahoo.com
Received: January 16, 2022 Peer-review started: January 16, 2022 First decision: February 8, 2022 Revised: February 13, 2022 Accepted: May 28, 2022 Article in press: May 28, 2022 Published online: June 27, 2022
Core Tip
Core Tip: Understanding the hepatic consequences of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection, as well as its molecular mechanism, has advanced significantly. Since the start of the pandemic, it appears that there has been thought that pre-existing chronic liver disease may predispose to deprived outcomes when combined with coronavirus disease 19 (COVID-19). Evidence suggests that COVID-19 patients have abnormal liver function more frequently, with more significant elevations in alanine aminotransferase and aspartate aminotransferase in severe COVID-19 patients than those with mild/moderate disease. In this review, we focus on the pathogenesis of SARS-CoV-2 infection in the liver, as well as the use of liver chemistry as a prognostic tool during COVID-19.
